Stock Track | Teva Pharmaceutical Soars 6.47% Intraday on Q2 Revenue Beat and Raised Sales Outlook

Stock Track07-29

Teva Pharmaceutical shares surged 6.47% intraday on Wednesday, extending gains from pre-market trading after the company released second-quarter results that topped revenue expectations and included a raised annual sales forecast.

The drugmaker reported quarterly revenue of $4.14 billion, exceeding the analyst consensus of $3.97 billion to $4.05 billion, driven by a 43% jump in sales from its three key brand-name products to $1 billion. Teva lifted its full-year sales guidance to a range of $16.5 billion to $16.85 billion, up from the prior $16.4 billion to $16.8 billion, and maintained its adjusted earnings per share outlook of $1.91 to $2.11.

While adjusted EPS came in at just $0.02, far below the $0.25 estimate due partly to acquisition-related charges, the top-line strength and improved guidance appeared to dominate investor sentiment. The market’s positive reaction suggests confidence in Teva’s ongoing pivot toward higher-growth brand-name therapies, even as generic drug sales faced headwinds.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1140913410?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-29 21:34","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1140913410","market":"sg","top_or_hot":-1,"title":"Stock Track | Teva Pharmaceutical Soars 6.47% Intraday on Q2 Revenue Beat and Raised Sales Outlook","media":"Stock Track","content":"<p>Teva Pharmaceutical shares surged 6.47% intraday on Wednesday, extending gains from pre-market trading after the company released second-quarter results that topped revenue expectations and included a raised annual sales forecast.</p><p>The drugmaker reported quarterly revenue of $4.14 billion, exceeding the analyst consensus of $3.97 billion to $4.05 billion, driven by a 43% jump in sales from its three key brand-name products to $1 billion. Teva lifted its full-year sales guidance to a range of $16.5 billion to $16.85 billion, up from the prior $16.4 billion to $16.8 billion, and maintained its adjusted earnings per share outlook of $1.91 to $2.11.</p><p>While adjusted EPS came in at just $0.02, far below the $0.25 estimate due partly to acquisition-related charges, the top-line strength and improved guidance appeared to dominate investor sentiment. The market’s positive reaction suggests confidence in Teva’s ongoing pivot toward higher-growth brand-name therapies, even as generic drug sales faced headwinds.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Teva Pharmaceutical Soars 6.47% Intraday on Q2 Revenue Beat and Raised Sales Outlook</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Teva Pharmaceutical Soars 6.47% Intraday on Q2 Revenue Beat and Raised Sales Outlook\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-07-29 21:34</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Teva Pharmaceutical shares surged 6.47% intraday on Wednesday, extending gains from pre-market trading after the company released second-quarter results that topped revenue expectations and included a raised annual sales forecast.</p><p>The drugmaker reported quarterly revenue of $4.14 billion, exceeding the analyst consensus of $3.97 billion to $4.05 billion, driven by a 43% jump in sales from its three key brand-name products to $1 billion. Teva lifted its full-year sales guidance to a range of $16.5 billion to $16.85 billion, up from the prior $16.4 billion to $16.8 billion, and maintained its adjusted earnings per share outlook of $1.91 to $2.11.</p><p>While adjusted EPS came in at just $0.02, far below the $0.25 estimate due partly to acquisition-related charges, the top-line strength and improved guidance appeared to dominate investor sentiment. The market’s positive reaction suggests confidence in Teva’s ongoing pivot toward higher-growth brand-name therapies, even as generic drug sales faced headwinds.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"TEVA","symbol_name":"梯瓦制药","start_time":0,"source_url":"","article_id":"1140913410","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1140913410","pubTimestamp":1785332061,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Teva Pharmaceutical shares surged 6.47% intraday on Wednesday, extending gains from pre-market trading after the company released second-quarter results that topped revenue expectations and included...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"TEVA":"梯瓦制药"},"translate_title":"股票跟踪 | 梯瓦制药第二季度收入超出预期并上调销售前景，盘中飙升 6.47%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TEVA":1},"content_text":"Teva Pharmaceutical shares surged 6.47% intraday on Wednesday, extending gains from pre-market trading after the company released second-quarter results that topped revenue expectations and included a raised annual sales forecast.The drugmaker reported quarterly revenue of $4.14 billion, exceeding the analyst consensus of $3.97 billion to $4.05 billion, driven by a 43% jump in sales from its three key brand-name products to $1 billion. Teva lifted its full-year sales guidance to a range of $16.5 billion to $16.85 billion, up from the prior $16.4 billion to $16.8 billion, and maintained its adjusted earnings per share outlook of $1.91 to $2.11.While adjusted EPS came in at just $0.02, far below the $0.25 estimate due partly to acquisition-related charges, the top-line strength and improved guidance appeared to dominate investor sentiment. The market’s positive reaction suggests confidence in Teva’s ongoing pivot toward higher-growth brand-name therapies, even as generic drug sales faced headwinds.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.47.1","shortVersion":"4.47.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1140913410","isCrawlerRequest":true}